rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

908 Devices Inc.

MASS · Nasdaq

Health CareLife-science toolsLeading

MASS stood above a rising 150-day average in 23 of the last 52 weekly readings, including each of the last 18 weeks. It is 31.9% above that average now. Life Science Tools & Research Services: 54% of its 79 stocks in an uptrend (+4 points in four weeks); Health Care: 26% (−10 points in four weeks).

Statistics

Rotation
Leading
Weeks in an uptrend
18 in a row
Industry in uptrend
54% +4 in 4 wk
Insider buys, 12 months
$0
Insider sales, 12 months
$19.3M
Officials’ trades on record
0
Institutions holding
109 (+1)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 23 of 52 weeks.

20 Apr – 19 Oct
27%44%61%Apr 26Jun 26Jul 26Sep 26Oct 26

Life-science tools: About half its stocks are in an uptrend and the share has been climbing. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
−$6.1M$0Nov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months0
Sale orders, 12 months56
Buyers · sellers0 · 6
WhoDidSharesTraded
Christopher D. BrownDirectorsold30,000at $11.897 Oct 2026filed 9 Oct 2026
Joseph H. Griffith IVChief Financial Officersold5,000at $13.036 Oct 2026filed 8 Oct 2026
Awm Investment Company, Inc.10% ownersold18,000at $11.5229 Sep 2026filed 1 Oct 2026
Awm Investment Company, Inc.10% ownersold24,000at $11.3624 Sep 2026filed 25 Sep 2026
Awm Investment Company, Inc.10% ownersold1,000at $11.2523 Sep 2026filed 25 Sep 2026
John KennewegSVP, Sales & Product Marketingsold5,257at $10.2217 Sep 2026filed 17 Sep 2026
John KennewegSVP, Sales & Product Marketingsold21,399at $10.1116 Sep 2026filed 17 Sep 2026
John KennewegSVP, Sales & Product Marketingsold1,000at $10.0015 Sep 2026filed 17 Sep 2026
Christopher D. BrownDirectorsold30,000at $10.582 Sep 2026filed 4 Sep 2026
Joseph H. Griffith IVChief Financial Officersold11,459at $10.9525 Aug 2026filed 27 Aug 2026
Awm Investment Company, Inc.10% ownersold41,578at $10.6121 Aug 2026filed 24 Aug 2026
Awm Investment Company, Inc.10% ownersold8,422at $10.5220 Aug 2026filed 24 Aug 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders109+1 on the quarter
New · exited17 · 15
Reported value$244.9M

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
First Light Asset Management, LLCadded · filed 14 Aug 20266,282,804$54.7M+210,241+3.5%
AWM Investment Company, Inc.reduced · filed 14 Aug 20264,879,773$42.5M-320,151−6.2%
ARK Investment Management LLCadded · filed 14 Aug 20262,027,920$17.6M+81,235+4.2%
BlackRock, Inc.added · filed 7 Aug 20261,944,236$16.9M+176,920+10.0%
NEEDHAM INVESTMENT MANAGEMENT LLCadded · filed 14 Aug 20261,820,620$15.8M+580,620+46.8%
VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 20261,291,570$11.2M+172,334+15.4%
First Eagle Investment Management, LLCadded · filed 5 Aug 2026929,985$8.1M+126,379+15.7%
GEODE CAPITAL MANAGEMENT, LLCadded · filed 12 Aug 2026761,797$6.6M+66,342+9.5%
Granahan Investment Management, LLCreduced · filed 14 Aug 2026692,092$6.0M-2,978−0.4%
STATE STREET CORPreduced · filed 7 Aug 2026606,560$5.3M-19,332−3.1%
31 Mar 2023 – 30 Jun 2026
6989108Mar 23Dec 23Dec 24Sep 25Jun 26

News

No headline names it lately.

Everyone who traded it

Christopher D. Brown Company insiderDirector · last 7 Oct 20260 · 38
Joseph H. Griffith IV Company insiderChief Financial Officer · last 6 Oct 20260 · 26
AWM Investment Company, Inc. Company insider10% owner · last 29 Sep 20260 · 16
John Kenneweg Company insiderSVP, Sales & Product Marketing · last 17 Sep 20260 · 16
Kevin J. Knopp Company insiderPresident and CEO · last 17 Aug 20267 · 40
Brandi C. Vann Company insiderDirector · last 1 Aug 20260 · 0
Michele M. Leonhart Company insiderDirector · last 25 Jun 20260 · 0
Anthony Hunt Company insiderDirector · last 11 Jun 20260 · 0
E. Kevin Hrusovsky Company insiderDirector · last 11 Jun 20261 · 0
Fenel M. Eloi Company insiderDirector · last 11 Jun 20260 · 0
Keith Crandell Company insiderDirector · last 11 Jun 20261 · 0
Mark Spoto Company insiderDirector · last 11 Jun 20263 · 0

Same industry

OABI OmniAbLeading+67%
TXG 10x GenomicsLeading+59%
AVTR AvantorLeading+45%
ILMN IlluminaLeading+44%
RVTY RevvityLeading+35%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Profit per saleFY 2025 · to 31 Dec 202550.6%
Operating profit marginFY 2025 · to 31 Dec 2025-70.1%
Free cash flow marginFY 2025 · to 31 Dec 2025-43.9%
Return on capital employedFY 2025 · to 31 Dec 2025-25.3%
Cash conversionFY 2025 · to 31 Dec 2025-122%
Research spendFY 2025 · to 31 Dec 202527.7%
Share count trendFY 2025 · to 4 Mar 20262.9%
Cash and equivalentsFY 2025 · to 31 Dec 2025$70.5M
Free cash flowFY 2025 · to 31 Dec 2025−$24.6M

Analyst forecasts

No analyst forecasts yet.